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Abstract 
Background: Brain natriuretic peptide (BNP) is an important predictor of outcomes in patients with heart failure 
but the prognostic value of BNP elevation in patients with myocardial infarction (MI) is not completely defined. 
This study aims to identify the prognostic value of BNP in patients with MI. 
Materials and Methods: We studied patients with MI who were hospitalized in the Coronary Care Unit of Imam 
Hossein Hospital. Patients' demographic data, past medical and drug history besides echocardiography report and 
BNP levels were documented during the hospital stay and echocardiography was repeated after 3 months. 
Results: This prospective observational cross-section study was done between January 2018 through January 
2019. During the study period, 124 patients were recruited. There was significant negative correlation between 
BNP levels and ejection fraction (P=0.001), systolic blood pressure (P=0.012), diastolic blood pressure 
(P=0.003) and ratio between early mitral inflow velocity and early diastolic mitral annular velocity (E/e') 
(P=0.03) and EF in follow up (P=0.001). The correlation between BNP levels with infarction location (P=0.40), 
arterial involvement in the left main coronary artery (P=0.15), left anterior descending artery (P=0.53), left 
circumflex artery (P= 0.97), right coronary artery (P=0.50) and hospital stay (P=0.66) were not significant. 
Conclusion: BNP is a valuable marker for predicting prognosis in patients with the acute coronary syndrome. 
Also, it could be considered as a prognostic long-term marker for predicting the EF of patients with AMI. 
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Myocardial infarction (MI) is considered as a 
subdivision of a spectrum referred to as Ischemic heart 
disease (IHD) which is the leading cause of death 
worldwide. World Health Organization (WHO) 
reported more than 9 million deaths in 2016 worldwide 
due to IHD1. 
Early diagnosis and successful myocardial reperfusion 
is the most effective plan for decreasing mortality and 
morbidity rate in MI patients2. 
Due to the correlation between early therapy and 
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reduced mortality among patients with MI, It is 
necessary to use noninvasive imaging techniques, for 
instance, Echocardiography and precise markers for 
diagnostic evaluation and estimation of severity and 
prognosis of the dysfunction as soon as possible3. 
Brain natriuretic peptide (BNP), a cardiac hormone 
selectively released from ventricles, increased in 
response to left ventricular (LV) volume expansion, 
decreased oxygen supply, acute myocardial infarction 
(MI) and chronic cardiac heart failure (HF)4–6. 
BNP is a 32-amino acid peptide which acts as a strong 
vasodilator and a natriuretic factor that adjust salt and 
water homeostasis4,7. 
Previous studies demonstrated that serum levels of 
BNP present a biphasic model after AMI8–10, with the 
leading rises happening almost 24 hours after the 
onset as a result of ischemia of myocardial cells and 
the latter rises 3–5 days after the onset due to increased 
wall stress of the left ventricle11. 
Corroborative evidence had shown the 
prognosticative importance of BNP during the acute 
phase of MI. In addition, evidence expressing that 
alteration in plasma BNP level, measured in acute 
coronary syndromes, coordinate with the mortality 
rate and extension of myocardial infarction12,13. 
This study designed for clarification of the predictive 
value of BNP serum levels for left ventricular function 
assessed by echocardiography in MI patients. 
Methods 
The study population was 124 consecutive patients 
admitted to the Imam Hossein Hospital (Tehran, Iran) 
from January 2018 through January 2019 with acute 
MI. The study protocol was approved by the ethics 
committee of the Shahid Beheshti University of 
Medical Sciences (IR.SBMU.MSP.REC.1398.150). 
At first, written informed consents for participation in 
the study were collected by all patients. 
The diagnosis of acute MI was confirmed via the 
Universal Definition of Myocardial Infarction14. 
The baseline patient characteristics, including the 
clinical parameters and the biochemical data, were 
collected at hospitalization and three months after 
discharge by a cardiology resident. 
During hospital stay (after the second day of 
admission) blood samples for determination of the 
BNP level and transthoracic echocardiography (TTE) 
were taken for all the patients. 
All statistical analyses were performed using SPSS for 
Windows (Version 21.0; SPSS Inc., Chicago, IL, 
USA). Quantitative data were tested for normality of 
distributions by Kolmogorov–Smirnov test, and then 
compared by Unpaired Student’s t-test, Mann-Whitney 
U test for normal and abnormal data, respectively 
(value of the Kolmogorov-Smirnov Test is greater than 
0.05 the data is normal). Qualitative data were analyzed 
by the Chi-square test, and a P-value of < 0.05 was 
considered significant. 
Results 
Patients' demographic data and past medical history 
including hypertension, hyperlipidemia, and diabetic 
subjects, and the other characteristics were comparable, 
are summarized in table 1. 
The mean plasma BNP level in patients was 
1217.33±1756.99 pg/ml. There was a weak negative 
correlation between BNP levels of AMI patients with 
systolic blood pressure (P=0.012, r=-0.24) and diastolic 
blood pressure (P =0.003, r=-0.28). Data are shown in 
Figure 1. 
The site of infarction was anterior in 60.18% (mean 
BNP level =1416.22±2087.76 pg/ml), isolated inferior 
wall infarction in 36.11(929.23±1177.33 pg/ml), 
inferior right ventricle in 3.7% (1075.50±956.16 pg/ml) 
of the patients. There was no significant relationship 
between BNP levels and infarction location (P=0.18, 
r=0.13). 
The average of left ventricular EF in the patients was 
48.49 % ±10.31%, and there was a significant reverse 
association between BNP level and EF (P=0.001, r=-
0.39) (Figure 2), besides that there was a slight 
relationship between BNP level and the ratio between 
early mitral inflow velocity and early diastolic mitral 
annular velocity (E/e') (P=0.03, r=0.23). There were no 
significant association between BNP level and peak 
early filling (E) (P=0.95, r=0.006), peak velocity flow 
in late diastole (A) (P=0.84, r=-0.019), early diastolic 
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mitral annular velocity (e') (P=0.07, r=-0.17) and early 
to late diastolic transmitral flow velocity ratio (E/A) 
(P=0.92, r=0.01) Echocardiography findings are 
shown in Table 2. 





History dyslipidemia (%) 108 (87.1%) 
History hypertension (%) 80 (64.51%) 
History diabetes mellitus (%) 90 (72.58%) 
History myocardial infarction (%) 118 (95.16%) 
1BMI : Body mass index 
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Figure 2. Relationship BNP levels (pg/ml) and EF in hospital (EF) and EF  in  follow up( EFF) . 
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In this study, we investigated the association between 
BNP level across arterial disturbance in the left main 
coronary artery (LMCA), left anterior descending 
artery (LAD), left circumflex artery (LCX), and right 
coronary artery (RCA). The mean plasma BNP level 
in patients with LMCA involvement was 2054.50 
±3526.62. There was no significant correlation 
between BNP level and LMCA disturbance (P= 0.15, 
r=0.14). 
In the current study, 45.96% of patients did not have 
LAD significant stenosis (mean 
BNP=941.17±1105.64). From the remaining patients, 
33.87% had proximal involvement (mean 
BNP=1237.57±2047.37), 6.45% had mid LAD stenosis 
(mean BNP=2235.63±3444.24) 
and 13.7% diagnosed with distal LAD stenosis (mean 
BNP=1470.25±1339.69). There was no significant 
correlation between BNP level and LAD stenosis 
(P=0.53, r=0.12). 
Also, there was no significant correlation between BNP 
level with LCX (P=0.97, r=0.01) and RCA stenosis 
(P=0.50, r=-0.06). Data are shown in table 3. 
Table 2: Echocardiography findings at baseline and follow up. 
Variables Base line Follow up 
Echo_EF 48.49±10.31 51.52±8.92 
E
1 75.93±18.85 76.58±15.69 
A
2 78.84±19.95 75.95±19.39 
E/E Prime3 10.48±2.97 10.93±1.81 
E To A4 1.01±0.34 1.2±1.15 
1 E: peak early filling 
2 A: peak velocity flow in late diastole 
3 E/E Prime: mitral inflow velocity and early diastolic mitral annular velocity 
4 E To A: early to late diastolic transmitral flow velocity ratio 
 
Table 3: Relationship between BNP levels and Location of coronary artery involvement. 





Yes 10 1136.04±1488.92  
NO 103 2054.50±3526.62 
LAD 
1 
Normal 57 941.17±1105.64  
Proximal 42 1237.57±2047.37 
Mid 8 2235.63±3444.24 
Distal 17 1470.25±1339.69 
LCX 
2 
Normal 103 1219.59±1791.23  
Proximal 0 0 
Mid 6 1016.83±1394.11 
Distal 4 1459.75±1661.74 
RCA 
3 
Normal 81 1284.98±1941.25  
Proximal 12 881.67±688.90 
Mid 16 1378.75±1478.02 
Distal 4 208.75±153.73 
1 LAD: left anterior descending artery 
2 LCX: left circumflex artery 
3 RCA: right coronary artery 
*significant stenosis means 50% or more 
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The mean hospital stay was 5.89±4.71 days. There 
was no relation between BNP levels of AMI patients 
and hospital stay in this study (P= 0.66, r=0.24) 
Fifty patients continued their follow up. The mean of 
EF was 51.59%±8.92%. There was a significant 
reverse association between BNP level and EF in 
follow up (P =0.001, r=-0.47). Data are shown in 
Figure 2. 
Discussion 
BNP is a valuable marker for predicting prognosis and 
severity of coronary artery disease in patients with the 
acute coronary syndrome. 
Several novel diagnostic advancements for 
assessment of AMI were seen in last decade, but 
mortality and morbidity rate of this status already 
stays high. In clinical practice, the blood level of BNP 
is used for the diagnosis and prognosis of heart failure, 
Recently BNP has been identified as an effective 
indicator for forecasting acute and chronic left 
ventricular impairment but its prognostic value in 
AMI is limited. Hence, this study intended to enhance 
the prognostic precision rate of this test by including 
numerous variables in the diagnostic test. 
The effect of left ventricular diastolic function on the 
secretion of B-type natriuretic peptide at rest and 
directly after exercise test in asymptomatic patients 
with diabetes or after myocardial infarction with 
preserved left ventricular systolic function was 
obvious15. 
In the present study, we understood that the ejection 
fraction was significantly decreased in patients with 
higher NT-proBNP. This outcome was analogous to 
that published by Radwan et al16. Besides that, we 
discovered a highly significant negative relationship 
between NT- proBNP and ejection fraction. This 
result was compatible with Namazi et al17. and was 
also supported by Emdin et al who realized that NT-
proBNP had admissible precision for recognizing 
heart failure due to left ventricular dysfunction18. 
Another attractive finding of the current study was 
patients who developed reduced ejection fraction after 
3 months had significantly higher mean values of BNP 
at 3 days, it was compatible with Manola et al and 
Clavel et al study11,19. 
Prior studies have shown that BNP is independent of 
incursive measurements in patients with HF, But the 
importance BNP in LV function in a patient with AMI 
is not clear20. 
Kaya et al showed that plasma BNP level in posterior 
AMI with right ventricular involvement is higher than 
isolated posterior infarction. Besides that, it was 
established, as well as pulmonary artery pressure—an 
indirect indicator of left ventricular diastolic 
dysfunction and left ventricular volume overload-, BNP 
levels were also enhanced 20, that result was also 
confirmed by Fazlinezhad et al study 15. But in our 
study, there have not clear predictive value for diastolic 
LV dysfunction. The result of our study was relevant 
with Dorobantu et al that showed that BNP 
measurements on admission and at 24 hours after 
revascularization have no predictive value for diastolic 
LV dysfunction, also these measurements have no 
predictive value for systolic LV dysfunction in inferior 
AMI patient21. 
We found no relationship between hospitalization 
periods and BNP level in patients with AMI which is 
not in concordance with the previous studies. Maybe it 
be justifiable due to the small number of patients, so 
data should be expounded cautiously. Eriten et al study 
in 2019 reported that patients with high BNP values had 
a longer hospitalization time than the normal group22. 
Our results did not show any correlation between LAD 
involvement and NT-proBNP level. This outcome was 
correlated with Namazi et al who showed that LAD 
involvement difference was significant comparing 
patients with UA, STEMI, and NSTEMI but there was 
no remarkable   difference in ACS patients without 
regarding subgroup17 but Sadanandan et al reported that 
higher NT-proBNP levels were found in patients with 
UA and NSTEMI with LAD involvement23. 
Conclusion 
Correlated with last studies plasma BNP level could be 
effective as an important predictor of left ventricular 
systolic dysfunction, as a reverse relation of BNP levels 
and LVEF at 3rd day and after 3 months is observed in 
AMI patients. Another echocardiography finding of 
this study is relationship between BNP level and ratio 
between early mitral inflow velocity and mitral annular 
early diastolic velocity. 
Beside that there is significant reverse relation of BNP 
and blood pressure is seen. Hence, it appears that 
measurement of plasma BNP level in early phase of 
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myocardial infarction may be useful as a non-invasive 
method for recognition of patients, at higher risk of 
complications. 
BNP is a valuable marker for predicting prognosis in 
patients with the acute coronary syndrome. BNP level 
correlates with systolic and diastolic blood pressure, 
and E/e' ratio. Also, it could be considered as a 
prognostic long-term marker for predicting the later 
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